- |||||||||| lesinidase alfa (SBC-103) / AstraZeneca
Trial completion, Trial primary completion date: Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB) (clinicaltrials.gov) - Jul 12, 2018 P1/2, N=11, Completed, Trial completion date: Apr 2018 --> Jul 2017 | Active, not recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Jul 2017; The Sponsor's decision to terminate the SBC-103 program was reached after review of the data from all interventional clinical studies of SBC-103. Active, not recruiting --> Completed | Trial primary completion date: Jul 2018 --> Oct 2017
- |||||||||| Trial completion: Natural History Studies of Mucopolysaccharidosis III (clinicaltrials.gov) - Nov 16, 2015
P=N/A, N=25, Completed, Initiation date: Oct 2013 --> May 2013 | Trial primary completion date: Jun 2017 --> May 2016 Recruiting --> Completed
- |||||||||| lesinidase alfa (SBC-103) / AstraZeneca
Enrollment closed: Safety, Pharmacokinetics, and Pharmacodynamics/Efficacy of SBC-103 in Mucopolysaccharidosis III, Type B (MPS IIIB) (clinicaltrials.gov) - Aug 11, 2015 P1/2, N=9, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||||||| Trial initiation date, Trial primary completion date: Natural History Studies of Mucopolysaccharidosis III (clinicaltrials.gov) - Feb 12, 2015
P=N/A, N=30, Recruiting, Trial primary completion date: Jun 2014 --> Jun 2017 Initiation date: Aug 2013 --> Feb 2014 | Trial primary completion date: Jul 2015 --> Oct 2015
|